Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock

Beta Bionics raises $172.5 million in a public offering to fund Mint commercialization, development activities and general corporate needs.

Rhea-AI Summary

Beta Bionics (BBNX) closed an underwritten public offering of common stock and pre-funded warrants, generating aggregate gross proceeds of $172.5 million before fees and expenses.

The company sold 7,652,175 shares of common stock at $17.25 per share and, to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at $17.2499 per warrant. Underwriters fully exercised their option to buy an additional 1,304,348 shares of common stock. Beta Bionics expects to use the net proceeds for general corporate purposes, including commercialization of its Mint™ product, expansion of manufacturing facilities, research and clinical development, product enhancements, potential strategic opportunities, and working capital and operating expenses. J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners served as joint book-running managers.

Positive

• $172.5 million in aggregate gross proceeds raised before fees and expenses
• Underwriters fully exercised their option for 1,304,348 additional shares
• Offering priced at $17.25 per share of common stock
• Proceeds earmarked for Mint™ commercialization, manufacturing expansion and development activities

Negative

• Equity and pre-funded warrant offering implies shareholder dilution, with proceeds before underwriting fees and expenses

News Explained

The completed raise adds $172.5 million gross before fees, while warrant conversion can further expand the share count.

For existing common holders, the completed issuance increases the share count, and exercise of the pre-funded warrants would add more shares, reducing each holder’s percentage ownership absent offsetting changes.

The pre-funded warrants were sold at nearly the common-stock price with a nominal exercise price, so conversion—not the closing itself—is the step that turns those warrant entitlements into shares.

As a historical sizing comparison, the $172.5 million gross offering equals 1073.6 days of the last reported quarterly operating cash use, while reported cash and investments equal 1401.1 days at that rate.

The final prospectus supplement is the document for the offering’s final fees and net proceeds; the release reports gross proceeds before underwriting discounts, commissions and expenses.

Sources and calculations

• Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock (2026-09-17)
• Dilution (2026-07-17)
• Pre-funded warrant (2026-07-17)
• Form S-3 purpose (2026-07-17)
• Prospectus supplement purpose (2026-07-17)
• Beta Bionics second-quarter 2026 fundamentals (2026Q2)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $172,500,000 / ($14,622,000 / 91) = 1073.6 days
• Available liquidity against the last reported quarterly operating outflow, in days at that rate ($44,318,000 + $136,171,000 + $44,648,000) / ($14,622,000 / 91) = 1401.1 days

Market Context

On Sep 15, BBNX’s offering-pricing announcement was followed by a 15.24% 24-hour move; the current r...

Analysis

On Sep 15, BBNX’s offering-pricing announcement was followed by a 15.24% 24-hour move; the current release confirms closing, full option exercise, and gross proceeds of $172.5 million.

Key Figures

Common Shares Offered: 7,652,175 shares Common Stock Price: $17.25 per share Pre-Funded Warrants: 1,043,484 shares +3 more

Common Shares Offered

7,652,175 shares

Public offering

Common Stock Price

$17.25 per share

Public offering

Pre-Funded Warrants

1,043,484 shares

Warrants issued in lieu of common stock to certain investors

Warrant Purchase Price

$17.2499 per warrant

Pre-funded warrants

Additional Shares Purchased

1,304,348 shares

Underwriters exercised their option in full

Gross Proceeds

$172.5 million

Including the underwriters’ option exercise; before discounts, commissions and expenses

Previous Offering Reports

2 past events · Latest: Sep 15

Same Type 2 events

1. Sep 15

   Offering pricing

   24h Move

   +15.2%

   Pricing established share and warrant terms before the offering’s subsequent closing.

2. Sep 15

   Offering proposal

   24h Move

   +15.2%

   Proposed base offering and underwriter option preceded final pricing and closing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement, form s-3

4 terms

underwritten public offering financial

"closing of its previously announced underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"pre-funded warrants to purchase 1,043,484 shares of common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"offered by Beta Bionics pursuant to a shelf registration statement"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. In addition, the underwriters exercised their option in full and purchased 1,304,348 additional shares of common stock. Including the option exercise, the aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics.

Beta Bionics expects to use the net proceeds from this offering for general corporate purposes, which may include costs associated with the commercialization of Mint^™, including expansion of Beta Bionics’ manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities and working capital and operating expenses.

J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners acted as the joint book-running managers for the offering.

The shares of common stock and pre-funded warrants described above were offered by Beta Bionics pursuant to a shelf registration statement on Form S-3 that was filed by Beta Bionics with the Securities and Exchange Commission (SEC) on February 24, 2026 and automatically became effective upon filing. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or from Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or from Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at 800-645-3751 (option #5), by email at WFScustomerservice@wellsfargo.com; or from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD.

Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Beta Bionics’ expectations with respect to the use of proceeds from the offering. For such statements, Beta Bionics claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Beta Bionics’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, those factors disclosed in Beta Bionics’ filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. These forward-looking statements represent Beta Bionics’ judgment as of the time of this release. Beta Bionics disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What securities did Beta Bionics offer and at what prices?

Beta Bionics offered 7,652,175 shares of common stock at $17.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per warrant, reflecting the public share price less the $0.0001 exercise price per share of each pre-funded warrant.

How will Beta Bionics use the net proceeds from this offering?

Beta Bionics expects to use the net proceeds for general corporate purposes, which may include costs associated with commercialization of Mint™, expansion of manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities, and working capital and operating expenses.

Who managed the Beta Bionics offering and under what registration statement was it made?

J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners acted as joint book-running managers. The common stock and pre-funded warrants were offered under a shelf registration statement on Form S-3 filed with the SEC on February 24, 2026, which became effective upon filing.

Where can investors obtain the final prospectus supplement for the offering?

The final prospectus supplement and accompanying prospectus are available on the SEC website at http://www.sec.gov. Copies may also be requested from J.P. Morgan Securities, Piper Sandler, Wells Fargo Securities, or Leerink Partners via their listed postal addresses, telephone numbers, or designated prospectus email contacts.